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Abstract
Specialists of human genetic diagnostics can be divided into four groups: Medical Geneticists (MDG), Genetic Nurses and/
or Counsellors (GN/GC), Clinical Laboratory Geneticists (CLG) and Laboratory Genetics Technicians (LGT). While the first
two groups are in direct patient contact, the work of the latter two, of equal importance for patient care, are often hidden as
they work behind the scenes. Herein the first study on the rights and duties of CLGs is presented. We present the results of a
survey performed in 35 European and 18 non-European countries with 100 participating specialists. A national CLG title is
available in 60% of European countries, and in 77% of the surveyed European countries a CLG can be the main responsible
head of the laboratory performing human genetic tests. However, in only 20% of European countries is a lab-report valid
with only a CLGs’ signature - even though the report is almost always formulated by the CLG, and an interpretation of the
obtained results in a clinical context by the CLG is expected in nearly 90% of European countries. Interestingly, CLGs see
patients in 30% of European countries, and are also regularly involved in student education. Overall, the CLG profession
includes numerous duties, which are quite similar in all regions of the world. Strikingly, the CLG’s rights and responsibilities
of leading a lab, or signing a report are regulated differently according to country specific regulations. Overall, the CLG is a
well-recognized profession worldwide and often working within a multidisciplinary team of human genetic diagnostics
professionals.
Introduction
Human genetic diagnostics is an emerging field, as knowl-
edge of underlying causes of inherited and acquired diseases
continues to grow exponentially [1]. This explosion has led to
the utilization of genetic testing by a wide range of healthcare
providers and patients, as direct to consumer tests have
allowed in home testing. As previously outlined [2], these
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developments are principally positive for patient care. Con-
versely, the quality of diagnostic tests offered by non-human
genetic trained specialists has become a subject of great
concern [2]. Thus, the European Board of Medical Genetics
(EBMG) together with the European Society of Human
Genetics (ESHG) and the EuroGentest, formerly a Network of
Excellence [3], now an integrated committee in the ESHG,
are providing tools for improving the quality of genetic testing
in Europe. This aim is to be achieved via: (i) certification of
specialists in human genetic diagnostics, and (ii) appropriate
genetic education for healthcare professionals. The work
carried out by this united group reveals the need for concerted
efforts to provide professional education to a range of health
professionals who play a role in the provision of genetic
testing [2, 4–6]. EBMG recommends that a human genetic
diagnostics multidisciplinary team is necessary, and is
exemplified by the inclusion of four groups of professional
experts [7]: Medical Geneticists (MDG), Genetic Nurses &
Genetics Counsellors (GN/GC), Clinical Laboratory Geneti-
cists (CLG) and Laboratory Genetics Technicians (LGT).
While the working conditions of MDGs and GNs/GCs have
been studied in detail [8–10], no such data is available con-
cerning rights and duties of CLGs or LGTs in different
countries. Herein we address this gap for CLGs through a
survey completed with over 50 countries worldwide and 100
participants.
Materials and methods
The survey (Supplementary data 1) included three blocks:
(1) two questions concerning anonymity and consent to
participate in the study, (2) six questions on demographic
background of the participant, and (3) 10 questions on
rights and duties of CLGs in the corresponding country.
This survey was sent from August to December 2017 to 222
CLGs in 88 countries. As Greece developed state recogni-
tion of a national CLG title in May 2018, this was included
in the study, accordingly. The final evaluation was com-
pleted through assessment of questions included in the
survey, with responses grouped by reported country (Sup-
plementary data 1):
1. Is there a national CLG-title in your country
If so:
a. Who provides the title?
b. Is the title state recognized as a profession?
2. Can a CLG be head of the laboratory performing
human genetic tests?
3. Is the report only valid with signature of an MD?
4. Who receives the final report?
5. Is the final report written by the CLG him-/herself?
6. Can further tests be suggested by the CLG?
7. Is there any result interpretation in report?
8. Does the CLG see and/or counsel patients?
9. Do CLGs teach at universities?
If so:
a. Is there a difference if they work in private or in
university laboratory?
Answers for survey questions (see Supplementary data
1: e.g., 7a, 7 h, 7j) led to inconclusive answers and/or
responses indicated the question was outside of the
knowledge of the interviewed participants (Supplementary
data 1: e.g., 4 and 9) and thus were excluded in the final
evaluation.
Results
Evaluable survey replies (Supplementary data 1) were
returned from 53/88 countries (60%; 35 European and 18
non-European countries) and 100/222 CLGs (45%). There
were 1 and 2 replies per country for 28 and 10 countries,
respectively, and 3 and 4 replies per country for 8 and 7
countries, respectively (Tab. 1).
The demographic data of the CLGs are presented by age-
characteristics in Fig. 1. The majority of respondents
worked at a hospital (60%), 11 and 12% in private and
research centers, respectively, and 17% worked at multiple
locations in parallel (Fig. 1a). The respondent ratio of
females to males was 2:1 (Fig. 1b); the age distribution and
work experience of participants are shown in Fig. 1c, d.
The responses of CLGs in the 53 countries were as
follows:
1. A national CLG-title is available in 60% of the 35
European countries surveyed, and only 28% of the 18
non-European (Fig. 2). National CLG titles were
provided by national human genetic societies or by
government. Exclusive to Australia and USA, CLG
titles issued by national human genetic societies are
state recognized as a legal professional title. In all
other countries, only certificates issued by the state are
recognized legally.
2. A CLG can be the main responsible head of the
laboratory performing human genetic tests in 73% of
the countries (in 10% there are some exceptions; see
footnotes Tab. 1), and in only 27% of the countries
must an MD be head of the laboratory. Within Europe
this accounts for 23% of the countries, i.e., in 77% of
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the European countries, a CLG may be head of a
human genetic diagnostic laboratory. This statistic
was reflected not surprisingly by the response of a
Dutch colleague to question 5b regarding MD
involvement: ‘Certainly a CLG can be responsible
head of a lab without an MD at his/ her side. How
could an MD be responsible for a lab?'.
3. A human genetic report is only valid with a signature
of an MD in 1/3 of the 53 countries. In Europe, the
signature of an MD is required for validity in only 1/5
of the countries. Interestingly, in some countries
instead of an MD, LGTs or a second CLG co-sign the
report. The validity of a report must be considered in
the context of reimbursement by health insurance
companies for services rendered. In USA, a report
with MD signature is reimbursed at a higher rate by
insurance companies, with reports of lower reimbur-
sement for an identical report with CLG signature
only. Conversely, e.g., in Netherlands and Switzer-
land it is logically concluded that the CLG signature is
the reason for reimbursement of laboratory diagnos-
tics given these tests are completed under their aegis.
4. In greater than 95% of the countries, the final report
goes to the MD who requisitioned the diagnostic test.
In fewer than 5% of countries, the patient or family
receives the report. In addition, in some countries
GNs/GCs or midwifes are recipients of reports.
5. In all European countries excluding Turkey, and only
5 non-European countries is the final report written by
the CLG.
6. Further tests can be suggested by a CLG in all
European countries excluding Russia and Turkey, and
6 non-European countries. In nearly 90% of the
countries, the expertise of CLGs is well-recognized
and reflected in their ability to requisition additional
tests to optimize patient care.
7. Result interpretation in a clinical context within the
report is expected in 31/35 European and 12/18 non-
European countries.
8. CLGs see and/or counsel patients alone or with MDs
in nearly 30% of European and 22% of non-European
Fig. 2 Availability of CLG title in 35 European and 17 non-European
countries is depicted; also indicated is whether the national CLG title is
state recognized as a legal profession. Abbreviations: gov government,
recogn. state recognized, soc society
Fig. 1 Statistics on participating
100 CLGs or equivalent
specialists interviewed in the
present study; type of center
witnesses are working within
(a), gender (b), age-distribution
(c) and years of work experience
(d) are given
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countries. In some countries participation in MD-lead
genetic counselling is obligatory during CLG educa-
tion.
9. CLGs teach at universities in all European countries,
excluding Denmark, and in all non-European coun-
tries excluding Iraq. In addition, teaching activities are
dependent on the employer (private or public).
Discussion
The present survey is, to the best of our knowledge, the first
performed on the working conditions of CLGs. The
responses were collected from 100 CLGs (Table 1). Their
age distribution and length of work experience support the
conclusions of this study as the answers were given by
experienced CLGs. Interestingly, the gender distribution of
CLGs participating in this survey is similar to previously
recognized findings of the CLG profession [2]. The
recruitment of participants was mainly based on personal
contacts of Thomas Liehr. Where possible, for each country
at least two CLGs were contacted; in addition, for each
country, the representatives as listed on https://www.ebmg.
eu/666.0.html as national contacts for ErCLG related
questions were included, and for non-European countries,
either registered affiliated ErCLGs and/or heads of corre-
sponding human genetic societies were contacted. How-
ever, for 28 countries only one contacted representative
participated. In general, the more people who replied for
each country, the more comprehensive the country specific
data became for data evaluation. This can be contributed to
the fact that a CLG knows best their working environment,
and may hold additional information regarding working
conditions of one or more laboratories within the country.
Differences from general rules are expected between
countries, given local specificities are abundant. Local
specificities were evident in this survey when contradictory
answers were given by participants in the same country, and
when multiple respondents reported detailed comments on
their country. However, conflicting questions and their
corresponding responses were thus excluded from final
evaluation. The results of this survey have been made freely
available on EBMG webpage (https://www.ebmg.eu/910.0.
html). New data on further countries and/or corrections on
information described herein are welcome and will be
uploaded when sent to Thomas.Liehr@med.uni-jena.de.
Herein, for the first time, the differences in working
conditions of CLG in non-European and European countries
are reported. In general, the profession is more widely
recognized in Europe, North-America, and Australia, rather
than other parts of the world. Accordingly, working con-
ditions of European, Canadian, US-American and
Australian CLGs are more regulated. Their duties and
influence on diagnostics are well-defined given their
nationally (Tab. 1) or on European level [2] certifiable
expertise. An EU wide recognition of the CLG title is more
than overdue, and is now possible following the rules of EU
Directive 2005/36/EC—policy developments (https://www.
eshg.org/fileadmin/eshg/EBMG/CLG/Direttiva_36_EN.
pdf) and the “Proposal for modernising the Professional
Qualifications Directive”= EU Directive 2013/55/EU
(https://www.eshg.org/fileadmin/eshg/EBMG/CLG/
Direttiva_55_EN.pdf), as at present (i.e. March 2018) Fin-
land, France, Greece, Italy, Hungary, Latvia, Poland, Slo-
venia and UK have national state recognized CLG titles.
Efforts to (re-)achive this kind of national recognition, are
currently underway in Portugal, Spain, Cyprus, and Den-
mark. The EBMG is in preparation of starting this EU CLG
recognition process (https://www.ebmg.eu/668.0.html).
As the majority of the surveyed countries not only allow
a CLG to be head of the laboratory performing human
genetic tests, but also to sign responsibly without an MD
demonstrates the already high acceptance rate of the CLG
profession. Examples from Norway, Poland, Pakistan,
Romania, Russia, Serbia, Switzerland, and Ukraine suggest
that even more responsibility in reporting can be success-
fully shared with LGTs, too.
Undoubtedly, reports of human genetic laboratory diag-
nostics primarily go via the requesting MD to the patient or
family nearly everywhere in the world. However, it is note-
worthy that GNs/GCs or midwifes (valid for result of non-
invasive prenatal diagnostic tests=NIPT [11]) can also be the
recipients and disseminators of reports in some countries. The
MDs and/or GNs/GCs are also responsible for the genetic
counselling and consulting of patients given genetic testing
results [8–10]. As such, as a minimum, during their education,
a CLG should experience patient counselling and become
familiar with the dissemination of genetic testing information
to patients, which will ensure all parties understand how
clinical queries are solved in part by human genetic laboratory
diagnostics [12]. In addition, nearly everywhere the report is
competently written by the CLG and (if applicable) further
tests are recommended, and further interpretation provided.
Finally, the CLG profession is warmly welcomed and inte-
grated into student education in nearly all surveyed countries.
Conclusions
CLG is a well-recognized profession worldwide. CLGs
have clearly defined rights and duties within a multi-
disciplinary team composed of four professions: MDGs,
GNs/GCs, CLGs and LGTs, working diligently to pro-
vide patients reliable diagnoses with a focus on ‘precision
medicine’ for all [13]. In Australia, North-America, and
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Table 1 Results of the survey in 53 countries and 100 CLGs
Country name Number of
witnesses
National
Title
(provided
by)
National
Title (state
recognized)
CLG
maybe
head of
a lab?
Report is
only
valid
with MD
sign.?
Report is
received
by…
Report is
written
by CLG?
Further
tests can
be sugge-
sted by
CLG?
Is there result
interpretation in
report?
CLGs see
/ counsel
patients?
CLGs teach at
university
when
working at
university/ in
private
institution?
1. Albania 1 N (n.a.) n.a. Y N P Y Y Y Y Y/N
2. Armenia 3 N (n.a.) n.a. Y N MD / P Y Y Y N Y/Y
3. Australia 1 Y (genet.
soc.)
Y Y N MD / P Y Y Y N Y/Y
4. Austria 2 Y (genet.
soc.)
Nb Y N MD Y Y Y N Y/N
5. Belarus 2 N (n.a.) n.a. N Y MD / P Y Y Y N Y/Y
6. Belgium 1 Y (genet.
soc.)
N Y Y MD Y Y Y N Y/N
7. Bosnia &
Herzegovina
1 N (n.a.) n.a. N Y MD / P Y Y Y Y Y/Y
8. Brazil 2 N (n.a.) n.a. Y N MD / P Y Y N N Y/N
9. Canada 3 Y (gouv.) Y Yc N MD Y Y Y N Y/N
10. China 1 N (n.a.) n.a. N Y MD / P N Y Nm Y Y/N
11. Croatia 4 N (n.a.) n.a. Yd N MD / P Y Y Y Y (rarely) Y/Y
12. Cuba 1 N (n.a.) n.a. Y Y n.a.p. N N n.a.p. N n.a.p.
13. Cyprus 1 N (n.a.) n.a. Y N MD Y Y Y Y Y/Y
14. Czech
Republic
1 Y (genet.
soc.)
N Y Y MD / P Y Y Y Y Y/Y
15. Denmark 1 Y (genet.
soc.)
N Y N MD Y Y Y N Y/Y
16. Ecuador 3 N (n.a.) n.a. N Y MD / P Y N N N Y/Y
17. Finland 4 Y (gouv.) Y Ye Ne MD Y Y Y N Y/Y
18. France 2 Y (gouv.) Y N Y MD / P Y Y Y N Y/Y
19. Germany 4 Y (genet.
soc.)
N N Y MD Y Y Y Nn Y/Y
20. Greece 4 Y (gouv.) Y Y N MD / P Y Y Y Y Y/Y
21. Hungary 4 Y (gouv.) Y Y N MD Y Y Y N Y/Y
22. India 1 N (n.a.) n.a. Y N MD / P Y Y Y N Y/Y
23. Iran 1 N (n.a.) n.a. Y N MD / P Y Y Y Y (rarely) Y/Y
24. Iraq 1 N (n.a.) n.a. N Y MD N N Y N N/N
25. Ireland 2 N (n.a.) n.a. N Ng MD Y Y Y Y Y/Y
26. Israel 3 Y (gouv.) Y (partly) Y N MD Y Y N N Y/N
27. Italy 4 Y (gouv.) Y Y N MD / P Y Y Y Yo Y/Y
28. Latvia 1 Y (gouv.) Y Y N MD Y Y Y N Y/Y
29. Macedonia 1 N (n.a.) n.a. N Y MD Y Y N N Y/N
30.
Montenegro
1 N (n.a.) n.a. N Y MD Y Y N N Y/N
31. Morocco 1 N (n.a.) n.a. N Y MD N Y N N Y/Y
32.
Netherlands
3 Y (genet.
soc.)
N Yf N MD / MW Y Y Y N Y/n.a.
33. Norway 1 Y (genet.
soc.)
N Y n.a.p. MD Yl Y Y N Y/n.a.
34. Pakistan 1 N (n.a.) n.a. Y Nh P Y Y Y Y Y/Y
35. Poland 4 Y (gouv.) Y Y Ni MD /
GC~GN
Y Y Y N Y/N
36. Portugal 1 Y (gouv.)a Y1 Y N MD Y Y Y N Y/Y
37. Romania 2 N (n.a.) n.a. Y Nh MD Y Y Y N Y/N
38. Russia 2 Y (gouv.) Y Ye Nh MD / P Y N N N Y/Y
39. Serbia 3 N (n.a.) n.a. Y Nh MD / P Y Y Y Np Y/Y
40. Slovakia 1 Y (genet.
soc.)
N Y N MD / P Y Y Y Y (rarely) Y/Y
41. Slovenia 2 Y (gouv.) Y Y N MD / P Y Y Y Np Y/n.a.
42. South
Africa
1 N (n.a.) n.a. Y N MD Y Y Y N Y/Y
43. Spain 2 N (n.a.) n.a. Y N MD Y Y Y Y Y/Y
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the majority of European countries, the vital role of CLG
in patient care is reflected highly given state recognition
of the profession. Thus, the European Union should wait
no longer, and move quickly forward with recognition of
the CLG profession as soon as possible, as previously
recommended by OECD (https://www.eshg.org/filea
dmin/www.eshg.org/documents/QAGuidelineseng.pdf).
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Table 1 (continued)
Country name Number of
witnesses
National
Title
(provided
by)
National
Title (state
recognized)
CLG
maybe
head of
a lab?
Report is
only
valid
with MD
sign.?
Report is
received
by…
Report is
written
by CLG?
Further
tests can
be sugge-
sted by
CLG?
Is there result
interpretation in
report?
CLGs see
/ counsel
patients?
CLGs teach at
university
when
working at
university/ in
private
institution?
44. Sweden 3 Y (genet.
soc.)
N Y N MD / MW
/ P
Y Y Y N Y/N
45.
Switzerland
1 Y (gouv.) Y Y Ni MD Y Y Y Nn Y/n.a.
46. Syria 1 N (n.a.) n.a. Y N MD / P Y Y Y Y n.a.p.
47. Tunisia 1 N (n.a.) n.a. N Yj MD Y N Y N Y/Y
48. Turkey 3 N (n.a.) n.a. N Y MD / P N N N N Y/n.a.
49. UK 1 Y (gouv.) Y Y N MD Y Y Y N Y/n.a.
50. Ukraine 2 N (n.a.) n.a. Y Ni MD / P Y Y Y N Y/Y
51. Uruguay 1 N (n.a.) n.a. N Y MD Y Y Y N Y/n.a.
52. USA 1 Y (genet.
soc.)
Y Y Nk MD /
GC~GN
Y Y Y N Y/Y
53. Yemen 1 N (n.a.) n.a. Y N MD / P Y N N N Y/Y
aat present not provided
bCLG profession mentioned in one law (see https://www.jusline.at/gesetz/gtg), but CLGs are not state recognized
cexcept for Quebec
dexception biochemical genetic reporting
eonly in private, not in hospital
flabs are part of Clinical Genetics departments
gbut there must be a second signature
hsecond signature by person doing lab work
isecond signature by person doing lab work or colleague
jreport exclusively with MD and no CLG signature
kreport without MD signature leads to lower reimbursement of insurance
lin parts prepared by technicians
mmaybe some in tumorcytogenetic cases
nhave to be present in genetic counselling several times during CLG training
oonly for pre-test counselling and informed consent explanation
16 can be present within a team;
Abbreviations: GC~GN= genetic counsellor or nurse; MD=medical doctor; MW=midwife; N= no; n.a.= not applicable; n.a.p.= no answer
provided; P= patient; Y= yes
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